Literature DB >> 20827674

Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease.

Tiago M Castilho1, Karen Goldsmith-Pestana, Caterin Lozano, Liliana Valderrama, Nancy G Saravia, Diane McMahon-Pratt.   

Abstract

Leishmania (Viannia) organisms are the most prevalent etiologic agents of human cutaneous leishmaniasis in the Americas. Nevertheless, our knowledge of the immunological mechanisms exploited by L. (Viannia) organisms remains limited and the mechanisms underlying disease are not well understood. Here, we report the development of a BALB/c mouse model of L. (V.) panamensis infection that is able to reproduce chronic disease, with persistent infection and clinically evident lesions for over 1 year. The immune response of the mouse resembles that found for L. (V.) panamensis-infected patients with chronic and recurrent lesions, presenting a mixed Th1/Th2 response with the presence of TNF-α, IFN-γ, IL-10 and IL-13. Using immunodeficient mice, the critical role for IL-13 and/or IL-4Rα in determining susceptibility to chronic infection was evident. With the induction of healing in the immunodeficient mice, increases in IFN-γ and IL-17 were found, concomitant with parasite control and elimination. Specifically, increases in CD4(+) (but not CD8(+)) T cells producing IFN-γ were observed. These results suggest that IL-13 represents an important target for disease control of L. (V.) panamensis infection. This murine model should be useful to further understand the pathology associated with chronic disease and to develop methods for the treatment and prevention of leishmaniasis caused by L. (Viannia) parasites.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20827674      PMCID: PMC3289133          DOI: 10.1002/eji.201040384

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  67 in total

1.  Proteomic analysis of Leishmania mexicana differentiation.

Authors:  Philip G Nugent; Saiful A Karsani; Robin Wait; Jane Tempero; Deborah F Smith
Journal:  Mol Biochem Parasitol       Date:  2004-07       Impact factor: 1.759

2.  Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide.

Authors:  Christine T McCusker; Yufa Wang; Jichuan Shan; Margaret W Kinyanjui; Annie Villeneuve; Husheem Michael; Elizabeth D Fixman
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

3.  Up-regulation of Th1-type responses in mucosal leishmaniasis patients.

Authors:  Olívia Bacellar; Hélio Lessa; Albert Schriefer; Paulo Machado; Amélia Ribeiro de Jesus; Walderez O Dutra; Kenneth J Gollob; Edgar M Carvalho
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody.

Authors:  María Colmenares; Stephanie L Constant; Peter E Kima; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease.

Authors:  Glória Bomfim; Bruno B Andrade; Silvane Santos; Jorge Clarêncio; Manoel Barral-Netto; Aldina Barral
Journal:  Am J Trop Med Hyg       Date:  2007-11       Impact factor: 2.345

6.  Leishmania braziliensis: partial control of experimental infection by interleukin-12 p40 deficient mice.

Authors:  Sebastião Martins de Souza-Neto; Cláudia Martins Carneiro; Leda Quercia Vieira; Luís Carlos Crocco Afonso
Journal:  Mem Inst Oswaldo Cruz       Date:  2004-07-19       Impact factor: 2.743

7.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?

Authors:  Mitzi G Mendonça; Maria E F de Brito; Eduardo H G Rodrigues; Valdir Bandeira; Márcio L Jardim; Frederico G C Abath
Journal:  J Infect Dis       Date:  2004-03-02       Impact factor: 5.226

9.  Cytokines, signaling pathways, and effector molecules required for the control of Leishmania (Viannia) braziliensis in mice.

Authors:  F Janaina Soares Rocha; Ulrike Schleicher; Jochen Mattner; Gottfried Alber; Christian Bogdan
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

10.  Endemically exposed asymptomatic individuals show no increase in the specific Leishmania (Viannia) panamensis-Th1 immune response in comparison to patients with localized cutaneous leishmaniasis.

Authors:  C M Trujillo; S M Robledo; J L Franco; I D Velez; K J Erb; P J Patiño
Journal:  Parasite Immunol       Date:  2002 Sep-Oct       Impact factor: 2.280

View more
  25 in total

1.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

Review 2.  The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis.

Authors:  Mary-Anne Hartley; Stefan Drexler; Catherine Ronet; Stephen M Beverley; Nicolas Fasel
Journal:  Trends Parasitol       Date:  2014-06-20

Review 3.  Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.

Authors:  Lynn Soong; Calvin A Henard; Peter C Melby
Journal:  Semin Immunopathol       Date:  2012-10-11       Impact factor: 9.623

4.  Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.

Authors:  Allison K Ehrlich; Olga L Fernández; Daniel Rodriguez-Pinto; Tiago M Castilho; Maria J Corral Caridad; Karen Goldsmith-Pestana; Nancy Gore Saravia; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

5.  Signal transducer and activator of transcription 1 (STAT-1) plays a critical role in control of Trypanosoma cruzi infection.

Authors:  Manjusha M Kulkarni; Sanjay Varikuti; Cesar Terrazas; Jennifer L Kimble; Abhay R Satoskar; Bradford S McGwire
Journal:  Immunology       Date:  2015-06       Impact factor: 7.397

6.  The immunotherapeutic role of regulatory T cells in Leishmania (Viannia) panamensis infection.

Authors:  Allison Ehrlich; Tiago Moreno Castilho; Karen Goldsmith-Pestana; Wook-Jin Chae; Alfred L M Bothwell; Tim Sparwasser; Diane McMahon-Pratt
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

7.  Animal models for the analysis of immune responses to leishmaniasis.

Authors:  D L Sacks; P C Melby
Journal:  Curr Protoc Immunol       Date:  2001-05

Review 8.  Drug discovery algorithm for cutaneous leishmaniasis.

Authors:  Max Grogl; Mark Hickman; William Ellis; Thomas Hudson; John S Lazo; Elizabeth R Sharlow; Jacob Johnson; Jonathan Berman; Richard J Sciotti
Journal:  Am J Trop Med Hyg       Date:  2013-02       Impact factor: 2.345

Review 9.  Eosinophils and mast cells in leishmaniasis.

Authors:  Nilda E Rodríguez; Mary E Wilson
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

10.  Human macrophage response to L. (Viannia) panamensis: microarray evidence for an early inflammatory response.

Authors:  Carolina Ramírez; Yira Díaz-Toro; Jair Tellez; Tiago M Castilho; Ricardo Rojas; Nicholas A Ettinger; Irina Tikhonova; Neal D Alexander; Liliana Valderrama; Janet Hager; Mary E Wilson; Aiping Lin; Hongyu Zhao; Nancy G Saravia; Diane McMahon-Pratt
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.